Business Context and Reporting Period
Company: 4D Molecular Therapeutics, Inc. (FDMT)
Filing Type: Form 8-K (Current Report)
Date of Report: July 18, 2026
Event: Announcement of positive 2-year data from the PRISM Phase 2b clinical trial evaluating 4D-150 for wet age-related macular degeneration (wet AMD).
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding clinical trial results and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The report details significant clinical milestones for the investigational therapy 4D-150:
- Trial Overview: The PRISM Phase 2b trial enrolled 45 patients at two dose levels (3E10 and 1E10 vg/eye). The 3E10 vg/eye dose was selected for the upcoming 4FRONT Phase 3 trials.
- Efficacy (2-Year Data):
- Consistent maintenance of best corrected visual acuity (BCVA).
- Consistent control of central subfield thickness (CST).
- Treatment Burden Reduction:
- Overall Cohort: 78% reduction (2.7 mean supplemental injections vs. 12.0 projected with aflibercept).
- Recently Diagnosed Subgroup: 87% reduction (1.6 mean supplemental injections vs. 12.0 projected).
- Safety Profile:
- 4D-150 remains well-tolerated across Phase 1/2a and 2b trials (n=71).
- Intraocular inflammation (IOI) occurred in 2.8% of patients within the first 28 weeks; these were transient and mild (1+).
- No new cases of inflammation observed after the first 28 weeks through 2 to 4 years of follow-up.
- No cases of hypotony, endophthalmitis, vasculitis, or choroidal effusions observed.
Guidance, Outlook, and Risks
Outlook: The company intends to proceed with the 4FRONT Phase 3 clinical trials using the 3E10 vg/eye dose based on the positive 2-year data and dose-response maintenance.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Actual results may differ materially due to risks described in the "Risk Factors" section of the most recent Form 10-Q (filed May 7, 2026). The company disclaims any obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the specific inclusion/exclusion criteria for the "recently diagnosed" subgroup to assess comparability with the Phase 3 population.
- Review the full safety data from the Phase 1/2a and 2b trials (n=71) for any adverse events not highlighted in the summary.
- Confirm the timeline and design details for the 4FRONT Phase 3 trials.
- Check the most recent Form 10-Q (May 7, 2026) for updated cash runway and burn rate, as this 8-K does not provide financial liquidity data.